-DOCSTART- -X- O
The -X- _ O
vaccine -X- _ O
elicitation -X- _ O
of -X- _ O
broadly -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
against -X- _ O
HIV-1 -X- _ B-Patient
is -X- _ O
a -X- _ O
long-sought -X- _ O
goal. -X- _ O
We -X- _ O
previously -X- _ O
reported -X- _ O
the -X- _ O
amino-terminal -X- _ O
eight -X- _ O
residues -X- _ O
of -X- _ O
the -X- _ O
HIV-1-fusion -X- _ O
peptide -X- _ O
( -X- _ O
FP8 -X- _ O
) -X- _ O
– -X- _ O
when -X- _ O
conjugated -X- _ O
to -X- _ O
the -X- _ O
carrier -X- _ O
protein -X- _ O
, -X- _ O
keyhole -X- _ O
limpet -X- _ O
hemocyanin -X- _ O
( -X- _ O
KLH -X- _ O
) -X- _ O
– -X- _ O
to -X- _ O
be -X- _ O
capable -X- _ O
of -X- _ O
inducing -X- _ O
broadly -X- _ O
neutralizing -X- _ O
responses -X- _ O
against -X- _ O
HIV-1 -X- _ B-Patient
in -X- _ O
animal -X- _ O
models. -X- _ O
However -X- _ O
, -X- _ O
KLH -X- _ O
is -X- _ O
a -X- _ O
multi-subunit -X- _ O
particle -X- _ O
derived -X- _ O
from -X- _ O
a -X- _ O
natural -X- _ O
source -X- _ O
, -X- _ O
and -X- _ O
its -X- _ O
manufacture -X- _ O
as -X- _ O
a -X- _ O
clinical -X- _ O
product -X- _ O
remains -X- _ O
a -X- _ O
challenge. -X- _ O
Here -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
preclinical -X- _ O
development -X- _ O
of -X- _ O
recombinant -X- _ B-Intervention
tetanus -X- _ I-Intervention
toxoid -X- _ I-Intervention
heavy -X- _ I-Intervention
chain -X- _ I-Intervention
fragment -X- _ I-Intervention
( -X- _ I-Intervention
rTTHC -X- _ I-Intervention
) -X- _ I-Intervention
linked -X- _ I-Intervention
to -X- _ I-Intervention
FP8 -X- _ I-Intervention
( -X- _ I-Intervention
FP8-rTTHC -X- _ I-Intervention
) -X- _ I-Intervention
as -X- _ I-Intervention
a -X- _ I-Intervention
suitable -X- _ I-Intervention
FP-conjugate -X- _ I-Intervention
vaccine -X- _ I-Intervention
immunogen. -X- _ I-Intervention
We -X- _ O
assessed -X- _ O
16 -X- _ O
conjugates -X- _ O
, -X- _ O
made -X- _ O
by -X- _ O
coupling -X- _ O
the -X- _ O
4 -X- _ O
most -X- _ O
prevalent -X- _ O
FP8 -X- _ O
sequences -X- _ O
with -X- _ O
4 -X- _ O
carrier -X- _ O
proteins -X- _ O
: -X- _ O
the -X- _ O
aforementioned -X- _ O
KLH -X- _ O
and -X- _ O
rTTHC -X- _ O
; -X- _ O
the -X- _ O
H. -X- _ O
influenzae -X- _ O
protein -X- _ O
D -X- _ O
( -X- _ O
HiD -X- _ O
) -X- _ O
; -X- _ O
and -X- _ O
the -X- _ O
cross-reactive -X- _ O
material -X- _ O
from -X- _ O
diphtheria -X- _ O
toxin -X- _ O
( -X- _ O
CRM197 -X- _ O
) -X- _ O
. -X- _ O
While -X- _ B-Outcome
each -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
16 -X- _ I-Outcome
FP8-carrier -X- _ I-Outcome
conjugates -X- _ I-Outcome
could -X- _ I-Outcome
elicit -X- _ I-Outcome
HIV-1-neutralizing -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
rTTHC -X- _ I-Outcome
conjugates -X- _ I-Outcome
induced -X- _ I-Outcome
higher -X- _ I-Outcome
FP-directed -X- _ I-Outcome
responses -X- _ I-Outcome
overall. -X- _ I-Outcome
A -X- _ I-Outcome
Sulfo-SIAB -X- _ I-Outcome
linker -X- _ I-Outcome
yielded -X- _ I-Outcome
superior -X- _ I-Outcome
results -X- _ I-Outcome
over -X- _ I-Outcome
an -X- _ I-Outcome
SM -X- _ I-Outcome
( -X- _ I-Outcome
PEG -X- _ I-Outcome
) -X- _ I-Outcome
2 -X- _ I-Outcome
linker -X- _ I-Outcome
but -X- _ I-Outcome
combinations -X- _ I-Outcome
of -X- _ I-Outcome
carriers -X- _ I-Outcome
, -X- _ I-Outcome
conjugation -X- _ I-Outcome
ratio -X- _ I-Outcome
of -X- _ I-Outcome
peptide -X- _ I-Outcome
to -X- _ I-Outcome
carrier -X- _ I-Outcome
, -X- _ I-Outcome
or -X- _ I-Outcome
choice -X- _ I-Outcome
of -X- _ I-Outcome
adjuvant -X- _ I-Outcome
( -X- _ I-Outcome
Adjuplex -X- _ I-Outcome
or -X- _ I-Outcome
Alum -X- _ I-Outcome
) -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
significantly -X- _ I-Outcome
impact -X- _ I-Outcome
elicited -X- _ I-Outcome
FP-directed -X- _ I-Outcome
neutralizing -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
mice. -X- _ I-Outcome
Overall -X- _ I-Outcome
, -X- _ I-Outcome
SIAB-linked -X- _ I-Outcome
FP8-rTTHC -X- _ I-Outcome
appears -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
a -X- _ I-Outcome
promising -X- _ I-Outcome
vaccine -X- _ I-Outcome
candidate -X- _ I-Outcome
for -X- _ I-Outcome
advancing -X- _ I-Outcome
to -X- _ I-Outcome
clinical -X- _ I-Outcome
assessment -X- _ I-Outcome
. -X- _ O

